Immunogenicity and tolerability of a heterologous booster typhoid conjugate vaccine (TCV) five to six years after primary vaccination in Burkinabe Children: An open-label, non-randomized follow-up of a phase 2 trial cohort
Typhoid fever remains a major public health challenge in low- and middle-income countries. In 2018, the World Health Organization recommended a single dose of typhoid conjugate vaccine (TCV) for routine immunization in endemic settings; however, evidence to inform booster dosing remains limited. This study evaluated th...